{
  "docId": "019de073-9ed2-75f5-b4c4-69324b7a8310",
  "docSlug": "d4b095284b050177fedb9bcc804883cf",
  "documentTitle": "Albireo Pharma | Results Presentation Deck | 18 slides",
  "authorId": "albireo-pharma",
  "authorName": "Albireo Pharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 16,
  "pageCount": 18,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9ed2-75f5-b4c4-69324b7a8310/16",
  "deckHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310",
  "deckJsonHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310.json",
  "deckAnchorHref": "/decks/019de073-9ed2-75f5-b4c4-69324b7a8310#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 1,
        "x": 0,
        "y": 0.95
      },
      "kind": "other",
      "text": "For Media & Investors Only ©2022 Albireo Pharma, Inc. All rights reserved",
      "attrs": null,
      "subkind": "unclassified",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab749a32-15bc-4433-9dd6-34dcfc9a94d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "PEDFIC: 1st IBATi Phase 3 PFIC Study. Pruritus endpoint (p=0.004), Bile acids endpoint (p=0.003), Diarrhea vs placebo (9.5% vs 5.0%)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3efee1df-94f7-47fb-9c96-44a097a787a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.08,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "ASSERT: 1st IBATi Phase 3 ALGS Study. Pruritus endpoint (p=0.002), Bile acids endpoint (p=0.001), Diarrhea vs placebo (11.4% vs 5.9%)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d92c9a6-7688-45dd-88fa-bda4a7657bda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 1,
        "x": 0,
        "y": 0.82
      },
      "kind": "title",
      "text": "Compelling evidence for regulators, payers and prescribers",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79b2749a-a50a-459c-a63e-464a72917d79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Gold Standard Phase 3 Studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0fd7421d-0a01-47b1-93ba-e0f0dbf2f636",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}